Furiex Pharmaceuticals to Present at Cowen & Company 33rdAnnual Healthcare Conference
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Furiex Pharmaceuticals, Inc. (NAS: FURX) , a drug development collaboration company, announced today that June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex, is scheduled to present at the Cowen 33rd Annual Healthcare Conference in Boston, MA on Monday, March 4, 2013 at 2:10 p.m. ET. Dr. Almenoff will provide a corporate overview and discuss Furiex's therapeutic pipeline.
A live webcast of Furiex's presentation may be accessed through the Presentations & Events link in the Investors section of the company's website at www.furiex.com. A replay of the webcast will be available on Furiex's website for 90 days following the conference.
Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, three products on the market and a fourth approved in the United States but not yet launched. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.
Furiex Pharmaceuticals, Inc.
Sailash Patel, 919-456-7814
KEYWORDS: United States North America North Carolina
The article Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.